Global EYLEA Drug - A Breakthrough In Treatment Of Retinal Diseases

EYLEA (Aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor developed by Regeneron Pharmaceuticals and Bayer for the treatment of various retinal diseases. It was approved by the US FDA in 2011 for treatment of wet age-related macular degeneration (AMD) and has since gained approval for other retinal conditions like diabetic macular edema (DME), macular edema following retinal vein occlusion (RVO) and diabetic retinopathy (DR).

 EYLEA has emerged as a frontline drug owing to its superior efficacy compared to other anti-VEGF agents like Lucentis and Avastin. Let’s take a detailed look at EYLEA and its impact on global management of retinal diseases.

Clinical Efficacy in Major Retinal Diseases

Numerous phase III clinical trials established EYLEA as a highly efficacious treatment for multiple retinal conditions:

• Wet AMD: VIEW 1 and VIEW 2 trials showed EYLEA was superior to laser photocoagulation and as effective as monthly ranibizumab in improving visual acuity at 2 years.
• DME: VIVID-DME and VISTA-DME trials demonstrated non-inferiority of EYLEA over laser photocoagulation and superiority over monthly ranibizumab and bevacizumab in achieving significant vision gains.
• RVO: GALILEO and COPERNICUS trials found EYLEA to be superior to sham injections and as effective as ranibizumab in improving visual outcomes at 6 months in macular edema due to central and branch RVO.
• Proliferative DR: VIVID-DR trial showed EYLEA injections every 4 weeks resulted in significant vision improvement compared to laser panretinal photocoagulation at 24 weeks.

Global EYLEA Drug -  https://www.coherentmi.com/blog/global-eylea-drug-a-breakthrough-in-treatment-of-retinal-diseases-57